Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma. Lexatumumab can be used to study malignant pleural mesothelioma (MPM).
Molecular Weight:
143.6 (kDa)
CAS Number:
[845816-02-6]
Target:
Apoptosis
* VAT and and shipping costs not included. Errors and price changes excepted